Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of faricimab in patients with choroidal neovascularization secondary to pathologic myopia.

THE AIM OF THIS STUDY IS TO COMPARE THE EFFECTS, POSITIVE OR NEGATIVE, OF FARICIMAB WITH THOSE OF RANIBIZUMAB IN PATIENTS WITH CNVM. IN THIS STUDY YOU WILL BE ABLE TO RECEIVE EITHER FARICIMAB OR RANIBIZUMAB.

Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA
  • Code EudraCT: 2023-506707-25-00
  • Protocol number: CR44829
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.